Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma

McLean, LS; Lim, AM; Bressel, M; Thai, AA; Rischin, D

Author(s): McLean, LS; Lim, AM; Bressel, M; Thai, AA; Rischin, D;
Details: Publication Year 2024-03,Volume 41,Issue #3,Page 271-281
Journal Title: Drugs & Aging
Publication Type: Research article
Abstract: BACKGROUND: Older patients are often underrepresented in clinical trials owing to exclusionary comorbidities, which are more common with age. Chemotherapy is poorly tolerated in older comorbid advanced cutaneous squamous cell carcinoma (CSCC) patients; however, little is known on the efficacy and tolerability of immune-checkpoint inhibitors (ICIs) in this population. To our knowledge, this is the largest dedicated report on a cohort of older patients with advanced CSCC treated with immunotherapy to date. OBJECTIVE: The aim was to report outcomes of ICI use in a real-world older cohort with advanced CSCC. PATIENTS AND METHODS: A single-centre retrospective audit of all patients treated via an access scheme providing ICIs to patients with advanced CSCC was conducted. Participants were ≥ 70 years of age and had advanced CSCC not amenable to curative surgery or radiotherapy. Best overall response rate (ORR), 12-month overall survival (OS) and progression-free survival (PFS), and toxicity rates were assessed. RESULTS: A total of 53 patients were analysed. The median age was 81.8 years (range 70.1-96.8); 81% were male; 34% were immunocompromised; and 34% had an Eastern Cooperative Oncology Group (ECOG) performance status score of ≥ 2. The ORR was 57%, and 12-month OS and PFS were 63% (95% confidence interval [CI] 44-78) and 41% (95% CI 25-57), respectively. Thirty-two per cent developed an immune-related adverse event (irAE), but only two patients experienced a grade 3 irAE, with no treatment-related deaths. Higher ECOG score was associated with worse OS and PFS. No significant association was identified for increasing age, sex, Charlson Comorbidity Index score, or immunocompromised status. CONCLUSIONS: ICIs have demonstrated efficacy and have an acceptable safety profile among older patients with advanced CSCC, with comparable efficacy to what has been demonstrated in current clinical trials.
Publisher: Springer Nature
Keywords: Humans; Male; Aged; Aged, 80 and over; Female; *Carcinoma, Squamous Cell/drug therapy; *Skin Neoplasms/drug therapy; Immune Checkpoint Inhibitors/adverse effects; Retrospective Studies; Immunocompromised Host
Department(s): Medical Oncology; Biostatistics and Clinical Trials
Publisher's Version: https://doi.org/10.1007/s40266-024-01095-z
Open Access at Publisher's Site: https://doi.org/10.1007/s40266-024-01095-z
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-04-08 11:52:22

Last Modified: 2024-04-09 12:02:58